CURRICULUM VITAE

Alice Elizabeth (Ellie) Guardino, M.D./Ph.D.

PERSONAL DATA

Birth Date June 9, 1965

Birth Place San Francisco, California

Ethnicity Caucasian Citizenship USA

Marital Status Married, three children Business Address Clinical Cancer Center

875 Blake Wilbur

Stanford University Medical Center

Stanford, California 94305 <u>Guardino@Stanford.edu</u> (650) 723-6661 #14683

(650) 736-0519

ACADEMIC HISTORY

1987 UCLA, B.S.

1997 Georgetown University, M.D./Ph.D. (Microbiology and

Immunology)

Post-Doctoral And Residency Training

1997-2000 Internship and Residency in Internal Medicine, Harvard

University, Beth Israel Hospital, Boston, Massachusetts

2000-2004 Fellow, Department of Medicine, Division of Oncology, Stanford

University Medical Center, Stanford, California

Certification And Licenses

1997 Commonwealth of Massachusetts

2000 Board Certification, Internal Medicine

2000 State of California Medical License #A72090

2003 Board Certification, Medical Oncology

EMPLOYMENT HISTORY

1985	Stanford Childrens Hospital Autism Project
1985-1986	Behavioral Modification Therapist, UCLA Autism Project
1987-1989	Research Associate, Amgen Inc.
1989-1990	Research Associate, UCLA Department of Surgical Oncology/Department of Biology and Immunology
1991-1992	Columbia Hospital for Women
1992-1993	Sibley Hospital
2001-2002	San Jose Medical Hospital Oncology
2001-2002	Hope Medical Oncology Group
2003-2004	Clinical Instructor, Division of Oncology, Department of Medicine, Stanford University

HONORS AND AWARDS

1997	The Mario Mollari Award for excellence in Microbiology and Immunology
2003	AACR Translation Cancer Research Award
2004	AACR Leventhal Scholar in Cancer Research
2004	Fellowship, Yu and Bechmann – Genomics and Oncology

SOCIETY MEMBERSHIP

American Association for Cancer Research (AACR) American Society of Clinical Oncology Women in Cancer Research, AACR

MAJOR RESEARCH INTERESTS

Tumor Immunology, Medical Oncology

OTHER RELEVANT SKILLS AND TRAINING

Investigational New Drug (IND) Preparation and Submission (August 2003) – approval (November 2003) BB-IND 11227 Allogeneic Peripheral Blood Mononuclear Cell Derived Dendritic Cell Pulsed Ex-Vivo with Granulocyte Macrophage Colony-Stimulating Factor (Immunex), Interleukin-4 (R&D Systems), Tumor Necrosis Factor-alpha (R&D Systems), and Autologous Idiotype Keyhole Limpet Hemocyanin

Development and production of GMP grade Dendritic cells for clinical use

Development of GMP grade protein vaccines for clinical use

Clinical trial design, protocol development and IRB submissions (formal training done in Vail, Colorado at *Methods in Clinical Cancer Research* (July 2002)

Clinical trials Investigator

Preclinical development of whole tumor vaccines for lymphoma

SPONSORED RESEARCH

A Randomized Phase II trial Evaluating Patholologic Complete Response (pCR) in Clinical Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy with Sequential AC → Taxotere with and without Dual EGFR Kinase blockade by GSK572016 (Lapatinib) PI: Alice Guardino, MD/PhD Submitted

Phase II open label study of gemcitabine, paclitaxel and bevacizumab combination as first line treatment for metastatic breast cancer
PI: Alice Guardino, MD/PhD
Submitted

XRP9881B-3001 A randomized, open-label, phase III study of RPR109881 IV every 3 weeks versus capecitabine (Xeloda) tablets twice daily for 2 weeks in 3-week cycles in patients with metastatic breast cancer progressing after taxanes and anthracycline therapy

PI: Robert Carlson, MD

9/1/04 – present

A Phase II, Randomized, Double-blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients with Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Carcinoma Following Standard First Line Endocrine Therapy

PI: Robert Carlson 9/1/04 – present

SPO#28455: A Phase II Trial of thalidomide and capecitabine in metastatic renal cell carcinoma

PI: Sandy Srinivas, MD

6/1/03-present

A Phase 3 Trial to Evaluate the Safety and Efficacy of the Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH with GM-CSF, Compared to Non-Specific Immunotherapy, KLH with GM-CSF, in Patients with Follicular Non-Hodgkin's Lymphoma (Protocol: G2000-03)

PI: Ronald Levy, MD

6/1/03-8/1/04

CURRENT FUNDING AND GRANT SUPPORT

AACR Translational Cancer Research Fellowship
AACR-WICR Leventhal Scholarship
Albert Yu and Mary Bechmann CCIS Fellowship in Genomics and Oncology
BMT Program Project Grant Stanford University-Project 6
Combined Allogeneic Idiotype-KLH Pulsed Dendritic cells

PUBLICATIONS

Patents:

- 1. <u>Hastings, A.</u>, Wims, L. A., and Morrison, S. L. (1991). Chimeric murine/human antiidiotype monoclonal antibodies. Docket No. 85-368 (UCLA 91-023-01).
- 2. Morrison, S. L. <u>Hastings, A.</u>, and Wims, L. A. (1991). Cloning Vectors for Expressing PCR Generated variable regions as complete heavy and/or light chain (s). DKT. 38996.

Peer Reviewed Articles:

- 1. Lichenstein, H. S., <u>Hastings, A.E.</u>, Langley, K. E., Mendiaz, E. A., Rohde, M. F., Elmore, R., and Zukowski, M. M. (1990). Cloning and nucleotide sequence of the N-acetylmuramidase M1-encoding gene from *Streptomyces globispores*. Gene 88, 81-86.
- 2. <u>Hastings, A.</u>, Morrison, S. L., Kanda, S., Saxton, R. E., Irie, R. F. (1992). Production and characterization of a murine/human chimeric anti-idiotype antibody that mimics ganglioside. Cancer Research 52, 1681-1686.
- 3. Coloma, J. M., <u>Hastings, A.</u>, Wims, L. A., and Morrison, S. L. (1992). Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. Journal of Immunologic Methods 152(1), 89-104.
- 4. Wade, J. A., Hurley, C. K., <u>Hastings, A.</u>, Ehrenberg, P., Johnson, A. H., Martell, R. W., and du Toit, E. D. (1993). Combinatorial diversity in DR2 haplotypes. Tissue Antigens. 41, 113-118.
- 5. Posch, P. E., <u>Hastings, A.E.</u>, Rosen-Bronsen, S., Richert, J. R., and Hurley, C. K. (1996). The relative importance of individual DR binding motif positions as defined by peptide anchor analysis of influenza hemagglutinin peptide 306-318 and human myelin basic protein peptide 152-165 binding to several DR molecules: definition of a common extended DR binding motif. European Journal of Immunology. 26, 1884-1891.
- 6. <u>Hastings, A. E.</u>, Hurley, C.K, Robinson, E. D., Salerno, K., Hernandez, E., Richert, J. R. (1996). Molecular interactions between transfected human T cell receptor, immunodominant myelin basic protein peptide 152-170 and HLA-DR13. Journal of Immunology. 57, 3460-3471.
- 7. Wu, X-w, Robinson, E.D., de Kroon, C., Kattah, M., Bredy, B., <u>Guardino, AE.</u>, Long, S., Richert, J.R., Wang, S.: Structural basis for the T cell receptor recognition of myelin basic protein peptide 152-165/HLA DR1301 (submitted for publication).
- 8. Srinivas, S. and <u>Guardino</u>, <u>A.E.</u> (2004). Oral thalidomide in metastatic renal cell carcinoma: A phase II trial. British Journal of Cancer (submitted for publication).
- 9. <u>Guardino, A.E.</u> and Srinivas, S. (2004). A Non-Platinum Combination In Metastatic Transitional Cell Carcinoma. American Journal of Clinical Oncology (In press).

Book Chapters:

1. Morrison S. L., Coloma, M. J., Espinoza, D., <u>Hastings, A.</u>, Shin, S-U., Wims, L. A., and Wright, A. Vectors and approaches for the eukaryotic expression of antibodies and antibody fusion proteins. In *Antibody Engineering*, second edition. (1995). Borrebaeck, ed. (New York: W. H. Freeman), 267-293.

- 2. <u>Hastings, A.E.</u>, Richert, J.R.: Construction and Expression of Human TCR Chains in Murine Hybridoma T Cell Lines. In: The Antigen T Cell Receptor. Selected Protocols and Applications (Oksenberg, J.R., ed.), Landes Bioscience, Austin, TX, 1997, pp. 632-670
- 3. <u>Guardino, A.E.</u>, and Advani, R. Treatment Approach to Mantle Cell Lymphomas. In Clinical Malignant Hematology (2004). Sekeres, ed. (New York: McGraw-Hill) Chapter submission date-June 2004.

<u>Invited Presentations: (10)</u>

- Hastings, A. E., Robinson, E. D., Hurley, C. K., and Richert, J. R. (1995). Transfection of human alpha/beta TCR cDNA's from a myelin basic protein (MBP)-specific T cell clone. J. of Biological Chemistry, Supp. 21A, 120. *Oral presentation* and poster session at the Keystone Symposium, Control and Manipulation of Immune Response, March 16, 1995 in Taos, New Mexico.
- Hastings, A.E., Robinson, E. D., Hurley, C. K., and Richert, J. R. (1995). Development of a transfection system for myelin basic protein-specific human T-cell receptors. T cell receptor use in human autoimmune diseases. Annals of the New York Academy of Sciences. New York, New York. 756, 321-322. *Oral presentation* at the New York Acad. of Sciences, San Diego, CA, April, 1994.
- 4. <u>Hastings, A. E.</u>, Robinson, E. D., Hurley, C. K., and Richert, J. R. (1995). Molecular interactions of HLA-DR, myelin basic protein (MBP) peptide and human TCR. Presented poster and *oral presentation* at FASEB, T Cell Subsets and Disease, April 9, 1995 in Atlanta, Georgia.
- 5. Srinivas, Sandy and <u>Guardino</u>, <u>A.E.</u> (2001). Oral thalidomide in metastatic renal cell carcinoma: A phase II trial. Presented at ASCO 2002 meeting.
- 6. <u>Guardino, A.E.</u> and Srinivas, Sandy (2001). Phase II trial of gemcitabine and paclitaxel chemotherapy for advanced transitional cell carcinoma of the bladder. Presented at ASCO 2002 meeting.
- 7. <u>Guardino, A.E.</u>, and Levy, R. (2003). Turning Lymphoma cells into a tumor vaccine using soluble CD40L. Presented at AACR Annual meeting in Washington, DC, July 2003.
- 8. <u>Guardino, A.E.</u>, Czerwinski, D., Long, A., Donetz, A., and Levy, R. (2003) Generating a lymphoma vaccine using CD40 Ligand. Lymphoma-Specific T Lymphocytes are generated and expanded using soluble CD40 Ligand Activated Tumor and CD3/CD28 Beads. Presented at ASH Annual meeting in San Diego, CA, December 2003.
- 9. <u>Guardino, A.E., Czerwinski, D., Levy, R.</u> (2004) Generating a Lymphoma Vaccine Using CD40 Ligand. *Oral Presentation* at AACR Annual Meeting in Orlando, Florida, March 27-31, 2004.

Abstracts (20):

1. Hurley, C. K., <u>Hastings, A. E.</u>, Johnson, A.H., Richert, J., Posch, P.E. (1995). Critical Peptide anchor residues for different peptides that bind to an individual HLA-DR Molecule and for an

- individual peptide that binds to several HLA-DR molecules. Presented at FASEB, T Cell Subsets and Disease, April 9, 1995 in Atlanta, Georgia.
- 2. <u>Hastings, A.E.,</u> Robinson, E.D., Hurley, C.K., Richert, J.R. (1995). Myelin basic protein residues that contact human T-cell receptor and human lymphocyte antigen molecules. Presented at American Neurological Association 120th Annual meeting, October 22-25, 1995 in Washington D.C.
- 3. Richert, J.R., <u>Hastings, A.E.</u>, Robinson, E.D., Hurley, C.K. (1996). Residues on myelin basic protein fragment 152-165 contact the human T-cell receptor. Neurology 46, A279.
- 4. Robinson, E.D., <u>Hastings, A.E.</u>, Hurley, C.K., Richert, J.R. (1996). Recognition of myelin basic protein (MBP) by mutated human T cell receptors. Annals of Neurology V40, 521.
- 5. <u>Hastings, A.E.</u>, Hurley, C.K., Richert, J.R. (1997). Recognition of MBP by human T cell receptors mutated in the CDR3 regions. J. of Allergy and Clinical Immunology. V99, 5180 (abstract 726).
- 6. Richert, J.R., Wang, S., Robinson, E.D., Wu, X-W., <u>Hastings, A.E.</u> (1997). 3 Dimensional structure of a myelin basic protein peptide-HLA-TCR trimolecular complex. Brain Pathology V7, 1265.
- 7. Wang, S., Robinson, E.D., Wu, X-W., Hastings, A.E., Hurley, C.K., Richert, J.R. (1997). Modeling of a myelin basic protein-specific human T cell receptor. Annals of Neurology V42, 420.
- 8. <u>Guardino, A.E.</u>, Auffermann-Gretzinger, S., Stockerl-Goldstein, K.E., Taidi, B., Benike, C., Reichardt, V., Hajnal, R., Engleman, E., Blume, K.G., Levy, R. (2001) Idiotype Dendritic cell vaccines in multiple myeloma. Presented at Asilomar Oncology Conference.
- 9. <u>Guardino, A.E.</u> (2004) Neoadjuvant therapy in locally advanced breast cancer. Presented at Asilomar Conference, Monterey, California.